MM 302

Drug Profile

MM 302

Alternative Names: Nano-doxorubicin

Latest Information Update: 12 Jan 2017

Price : $50

At a glance

  • Originator HERMES BioSciences
  • Developer Merrimack Pharmaceuticals
  • Class Antineoplastics; Doxorubicins; Drug conjugates; Immunoconjugates
  • Mechanism of Action DNA intercalators; RNA synthesis inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No
  • Available For Licensing Yes - Breast cancer

Highest Development Phases

  • Phase II Breast cancer

Most Recent Events

  • 08 Jan 2017 MM 302 is available for licensing as of 08 Jan 2017.
  • 21 Dec 2016 Merrimack Pharmaceuticals terminates the phase II HERMIONE trial in Breast cancer due to the inability of MM 302 to demonstrate benefit over the comparator treatments
  • 07 Apr 2016 The University of California at San Francisco plans a pilot phase 0 trial for Solid tumours with brain metastases (Late-stage disease, Combination therapy, Second-line therapy or greater) in USA (IV) (NCT02735798)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top